Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin in Reduced Conditioning Allo-SCT for Aggressive NHL
NCT00607854Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Feb 2008
- Primary completion
- Feb 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL) and 4 more, sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Treatment-Related Mortality at 100 days. Started Feb 2008; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Burkitt lymphoma (BL)lymphoblastic lymphoma (LL)intravascular large B-cell lymphoma (IVLBCL)
Beyond the preview
Go deeper on NCT00607854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00607854.